GlassScriptPhysician profile
Craig Francis
NPI 1902481286
$7,291.40
in general payments reported to CMS, 2019-2025
22 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $533 · 2022: $1,486 · 2023: $2,342 · 2024: $1,872 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,260 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,260.08 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,503.01 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $946.95 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $941.11 | 2021-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $939.05 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $936.28 | 2021-2022 | |
| Alkermes, INC. | $567.61 | 2023-2025 | Lybalvi, Vivitrol, Aristada |
| Indivior INC. | $279.92 | 2022-2024 | Sublocade, Perseris |
| Lundbeck LLC | $271.23 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $179.78 | 2023 | Auvelity |
| Janssen Scientific Affairs, LLC | $150.00 | 2023 | Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $128.33 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $107.30 | 2023-2024 | Ingrezza |
| Braeburn INC. | $90.32 | 2023-2024 | Brixadi |
| Neuronetics, INC. | $80.11 | 2024-2025 | Neurostar Tms Therapy System |
| Vanda Pharmaceuticals INC. | $39.70 | 2022-2024 | Fanapt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $30.58 | 2023 | Latuda |
| Tris Pharma INC | $20.11 | 2024 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.05 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $17.14 | 2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $16.59 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $15.05 | 2024 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $13.18 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.